Inclusion Criteria:

1. Histologically (Primary tumor with ≥ 50% clear cell histomorphology) or cytologically
confirmed ovarian clear cell carcinoma The disease should be documented recurrence or
resistant to primary platinum and paclitaxel based adjuvant chemotherapy.

- Patients are relapsed, not amenable to curative surgery or radiotherapy.

- not considered to required palliative chemotherapy nor radiotherapy

- Abnormal elevated serum CA125 tumor marker for no measurable disease by physical
examination or image study, roentgenogram or computed tomography (CT) scan.
Serum level of CA125 is higher than 80 IU/ml, or serum level of CA125 is at
least 2 fold on day 14 than original serum level of CA125 which is higher than
35 IU/ml but less than 80 IU/ml on day 0.

2. Evidence of measurable disease according to the Response Evaluation Criteria in Solid
Tumors (RECIST) guidelines.

3. Female, 20 years of age or older.

4. GOG performance status of 0 - 2.

- GOG performance status 0-2

- Resolution of all acute toxic effects of prior chemotherapy, radiotherapy, or
surgery to NCI CTCAE grade ≤1(except for alopecia).

- Life expectancy of at least 8 weeks

5. Adequate organ function as defined by the following criteria:

- Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤2.5 x
upper limit of normal (ULN) or AST and ALT ≤5 x ULN if liver function
abnormalities are due to underlying malignancy (liver metastases)

- Total serum bilirubin ≤1.5 x ULN

- Absolute neutrophil count (ANC) ≥1500/µL

- Platelets ≥100,000/µL

- Hemoglobin ≥9.0 g/dL

- Serum creatinine ≤1.5 x ULN

- QTc interval ≤450 msec for males and ≤470 msec for females (based on a mean
value from 3 ECGs)

- Left ventricular ejection fraction (LVEF) ≥lower limit of institutional normal
(LLN) as assessed by multigated acquisition (MUGA) scan or echocardiogram

6. Signed and dated informed consent document indicating that the patient (or legally
acceptable representative) has been informed of all pertinent aspects of the trial
prior to enrollment.

7. Willingness and ability to comply with scheduled visits, treatment plans, laboratory
tests, and other study procedures.

Exclusion Criteria:

1. Any of the following: known, severe hypersensitivity to sunitinib or any of the
excipient of this product, unable to swallow sunitinib, previous treatment with
sunitinib

2. Major surgery or radiation therapy within 4 weeks of study treatment.

3. Evidence of tumor bleeding within 4 weeks of study treatment.

4. NCI CTCAE grade ≥3 hemorrhage within 4 weeks of study treatment.

5. Newly diagnosed CNS metastases that have not been adequately controlled

6. Ongoing cardiac dysrhythmias of grade ≥2.

7. Hypertension that cannot be controlled by medication (>150/100 mmHg despite optimal
medical therapy).

8. Any of the following within the 12 months prior to study treatment: myocardial
infarction, severe/unstable angina, coronary/peripheral artery bypass graft,
congestive heart failure, cerebrovascular accident including transient ischemic
attack, or pulmonary embolism.

9. Diagnosis of any second malignancy within the last 3 years, except basal cell
carcinoma, squamous cell skin cancer, or in situ carcinoma that has been adequately
treated with no evidence of recurrent disease for 12 months.

10. Ongoing treatment with therapeutic doses (with therapeutic INR levels) of coumarin
derivatives (low dose up to 2 mg PO daily for deep vein thrombosis prophylaxis is
allowed) or oral anti-vitamin K agents.

11. PT >1.5 x ULN

12. Known human immunodeficiency virus (HIV) infection.

13. Current treatment on another clinical trial.

14. Pregnancy or breastfeeding. Patients who are unwilling or unable to use adequate
contraception to prevent pregnancy during the study. All female patients with
reproductive potential must have a negative pregnancy test prior to study entry.